Monopar Therapeutics (MNPR) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 213 transactions totaling $45.1M, demonstrating a bearish sentiment with -$32.6M in net insider flow. The most recent transaction on Jan 1, 2026 involved a transaction of 2,000 shares valued at $0.
No significant insider buying has been recorded for MNPR in the recent period.
No significant insider selling has been recorded for MNPR in the recent period.
Based on recent SEC filings, insider sentiment for MNPR is bearish with an Insider Alignment Score of 14/100 and a net flow of -$32.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Monopar Therapeutics (MNPR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading MNPR stock, having executed 213 transactions in the past 90 days. The most active insider is Pharma Llc Tactic (Executive), who has made 6 transactions totaling $36.8M.
Get notified when executives and directors at MNPR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 1, 2026 | Rioux Patrice | Executive | Award | 2,000 | $N/A | $0 | |
| Dec 31, 2025 | Cittadine Andrew | Chief Operating Officer | Option Exercise | 4,326 | $N/A | $0 | C-Suite |
| Dec 31, 2025 | Cittadine Andrew | Chief Operating Officer | Payment | 1,889 | $65.30 | $123.4K | C-Suite |
| Dec 31, 2025 | Cittadine Andrew | Chief Operating Officer | Option Exercise | 4,326 | $N/A | $0 | C-Suite |
| Dec 31, 2025 | Robinson Chandler | Executive | Option Exercise | 8,724 | $N/A | $0 | |
| Dec 31, 2025 | Robinson Chandler | Executive | Payment | 2,558 | $65.30 | $167.0K | |
| Dec 31, 2025 | Robinson Chandler | Executive | Option Exercise | 8,724 | $N/A | $0 | |
| Dec 26, 2025 | Anh Vu Quan | Executive | Purchase | 1,500 | $69.95 | $104.9K | |
| Dec 18, 2025 | J. Klausner Arthur | Executive | Sale | 461 | $68.09 | $31.4K | |
| Dec 18, 2025 | J. Klausner Arthur | Executive | Sale | 4,660 | $67.06 | $312.5K | |
| Dec 16, 2025 | J. Klausner Arthur | Executive | Other | 7,710 | $N/A | $0 | |
| Dec 16, 2025 | Hendricks Diane | Executive | Other | 43,499 | $N/A | $0 | |
| Sep 30, 2025 | Robinson Chandler | Executive | Payment | 2,646 | $81.67 | $216.1K | |
| Sep 30, 2025 | Robinson Chandler | Executive | Option Exercise | 8,726 | $N/A | $0 | |
| Sep 30, 2025 | Cittadine Andrew | Executive | Payment | 1,896 | $81.67 | $154.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 11 | $38.9M | 83.9% |
Purchase(P) | 18 | $6.3M | 13.5% |
Payment(F) | 55 | $1.2M | 2.6% |
Exercise (Options)(X) | 4 | $425 | 0.0% |
Award(A) | 1 | $0 | 0.0% |
Exercise(M) | 121 | $0 | 0.0% |
Other(J) | 3 | $0 | 0.0% |
Insider selling pressure at Monopar Therapeutics has increased, with 14 insiders executing 213 transactions across all time. Total sales of $38.9M significantly outpace purchases of $6.3M, resulting in a net outflow of $32.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.